These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 2510509

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ, First MR, Hurtubise PE, Marmer DJ, Martin DM, Mansour ME, Melvin DB.
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES, Bruce DS, Josephson M, Cronin D, Newell KA, Millis JM, Piper JB, O'Laughlin R, Thistlethwaite JR.
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [Abstract] [Full Text] [Related]

  • 5. Clinical experience with Muromonab-CD3 monoclonal antibody (OKT3) in heart transplantation.
    Macris MP, Frazier OH, Lammermeier D, Radovancevic B, Duncan JM.
    J Heart Transplant; 1989 Aug; 8(4):281-7. PubMed ID: 2504894
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Quadruple immunosuppression: comparison of OKT3 and Minnesota antilymphocyte globulin.
    Light JA, Khawand N, Aquino A, Ali A, Korb S.
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):10-3. PubMed ID: 2510505
    [Abstract] [Full Text] [Related]

  • 8. Selective OKT3 induction therapy in adult cadaveric-donor renal transplant recipients.
    Thistlethwaite JR, Heffron TG, Stuart JK, Buckingham M, Stuart FP.
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):28-34. PubMed ID: 2510508
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
    Costanzo-Nordin MR, O'Sullivan EJ, Hubbell EA, Zucker MJ, Pifarre R, McManus BM, Winters GL, Scanlon PJ, Robinson JA.
    J Heart Transplant; 1989 Nov; 8(4):288-95. PubMed ID: 2504895
    [Abstract] [Full Text] [Related]

  • 11. Treatment with OKT3 and cyclosporine for acute allograft rejection.
    Schulak JA, Mayes JT, Hricik DE.
    Transplant Proc; 1991 Aug; 23(4):2119-22. PubMed ID: 1908150
    [Abstract] [Full Text] [Related]

  • 12. Antimouse antibody response after OKT3 administration for steroid resistant rejection.
    Kaiser BA, Palmer JA, Dunn SP, Mochon MA, Bartosh SM, Schulman SL, Polinsky MS, Baluarte HJ.
    Child Nephrol Urol; 1991 Aug; 11(4):190-2. PubMed ID: 1777898
    [Abstract] [Full Text] [Related]

  • 13. Effective induction immunosuppression for cadaver renal transplantation at the St. Francis Regional Medical Center.
    Shield CF.
    Clin Transpl; 1990 Aug; ():265-74. PubMed ID: 2129408
    [Abstract] [Full Text] [Related]

  • 14. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
    Woodle ES, Bruce DS, Josephson M, Newell KA, Piper JB, Millis JM, Cronin D, Whitman G, Ruebe M, Thistlethwaite JR.
    Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
    [Abstract] [Full Text] [Related]

  • 15. OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation.
    Hegewald MG, O'Connell JB, Renlund DG, Lee HR, Burton NA, Karwande SV, Jones KW, Lassetter JE, Bristow MR.
    J Heart Transplant; 1989 Aug; 8(4):303-9; discussion 309-10. PubMed ID: 2504897
    [Abstract] [Full Text] [Related]

  • 16. Comparison of Minnesota antilymphocyte globulin and OKT3 for induction of immunosuppression in renal transplant patients.
    Light JA, Khawand N, Ali A, Brems W, Aquino A.
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1738-40. PubMed ID: 2652569
    [Abstract] [Full Text] [Related]

  • 17. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection.
    Waid TH, Lucas BA, Amlot P, Janossy G, Yacoub M, Cammisuli S, Jezek D, Rhoades J, Brown S, Thompson JS.
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):61-70. PubMed ID: 2479265
    [Abstract] [Full Text] [Related]

  • 18. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
    Emre S, Gondolesi G, Polat K, Ben-Haim M, Artis T, Fishbein TM, Sheiner PA, Kim-Schluger L, Schwartz ME, Miller CM.
    Liver Transpl; 2001 Mar; 7(3):220-5. PubMed ID: 11244163
    [Abstract] [Full Text] [Related]

  • 19. Impact of first acute rejection episode and severity of rejection on cadaveric renal allograft survival.
    Hariharan S, Alexander JW, Schroeder TJ, First MR.
    Clin Transplant; 1996 Dec; 10(6 Pt 1):538-41. PubMed ID: 8996775
    [Abstract] [Full Text] [Related]

  • 20. Sensitization to OKT3 monoclonal antibody in heart transplantation: correlation with early allograft loss.
    O'Connell JB, Renlund DG, Hammond EH, Wittwer CT, Yowell RL, DeWitt CW, Jones KW, Gay WA, Menlove RL, Bristow MR.
    J Heart Lung Transplant; 1991 Dec; 10(2):217-21; discussion 221-2. PubMed ID: 1903303
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.